menu
    • menu

    Company profile for Interquim SA

    Interquim-PSE
    News
    New Studies Show Critical Push For Better PH-ILD Diagnosis And Treatment

    20 Nov 2024

    // PRESS RELEASE

    Discover our 2023 Sustainability Report

    07 Oct 2024

    // PRESS RELEASE

    Ferrer Advances Research Into PSP First Participant Ph II Trial

    08 Aug 2024

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Interquim

    Contact Supplier

    Website

    Biotech Digital Meet

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/VS2CVVLkaFs

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Related CompaniesRelated Companies

    About

    Interquim, founded in 1978, is now part of the Ferrer HealthTech division. Interquim specializes in the development of competitive processes for manufacturing high added-value APIs that meet stringent quality standards. Complying with European environmental and work safety regulations, Interquim’s products are exported to highly regulated pharmaceutical markets. Regulatory bodies and clients have approved its quality system and facilities. With state-of-the-art multi-production plants, drug synthesis, and quality-control labs, Interquim supports clients throughout the entire product lifecycle, from product development to marketing.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Interquim SASpain_new Flag
    Country
    Country
    Spain
    Address
    Address
    Carrer de Joan Buscallà, 10, 08173 Sant Cugat del Vallès (Barcelona)
    Telephone
    Telephone
    +34 935044200
    Client Email
    Email
    mheras@ferrer.com
    Client Website
    Website
    https://www.ferrer.com/en/our-activities/active-ingredients
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ferrerforgood/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ferrerforgood
    Contact Info
    Others

    Other Address:
    Production Joan Buscallà 10 08173 Sant Cugat del Vallès Barcelona, Spain

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/interquim-sa-party-content-4473.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/interquim-sa-party-content-58017.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/interquim-sa-party-content-79653.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024.  Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent.  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each.  The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders).  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available)    GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453   US$ 3,21,920   Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427   US$ 2,31,952 FDF—Foreign US$ 2,35,427   US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629   US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852   US$ 7,56,666 Small business generic drug applicant US$ 1,72,963   US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.   
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 6871

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions

    #PharmaFlow by PHARMACOMPASS
    24 Oct 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    New Studies Show Critical Push For Better PH-ILD Diagnosis And Treatment
    New Studies Show Critical Push For Better PH-ILD Diagnosis And Treatment

    20 Nov 2024

    // PRESS RELEASE

    https://www.ferrer.com/en/Ferrer_spearheads_two_European_studies_to_improve_the_diagnosis_and_treatment_of_pulmonary_hypertension_associated_with_interstitial_lung_disease

    PRESS RELEASE
    20 Nov 2024
    Share Share
    Discover our 2023 Sustainability Report
    Discover our 2023 Sustainability Report

    07 Oct 2024

    // PRESS RELEASE

    https://www.ferrer.com/sites/default/files/2024-07/Ferrer_Sustainability_Report_2023_web.pdf

    PRESS RELEASE
    07 Oct 2024
    Share Share
    Ferrer Advances Research Into PSP First Participant Ph II Trial
    Ferrer Advances Research Into PSP First Participant Ph II Trial

    08 Aug 2024

    // PRESS RELEASE

    https://www.ferrer.com/en/Ferrer-advances-research-Progressive-Supranuclear-Palsy-PSP

    PRESS RELEASE
    08 Aug 2024
    Share Share
    Ferrer obtains the distribution rights of a potential treatment for IPF & PPF
    Ferrer obtains the distribution rights of a potential treatment for IPF & PPF

    24 May 2024

    // PRESS RELEASE

    https://www.ferrer.com/en/Tyvaso-indications-idiopathic-pulmonary-fibrosis-progressive-pulmonary-fibrosis

    PRESS RELEASE
    24 May 2024
    Share Share
    People living with pulmonary hypertension call for better psychological support
    People living with pulmonary hypertension call for better psychological support

    21 Apr 2024

    // PRESS RELEASE

    https://www.ferrer.com/en/pacientes-hipertension-pulmonar-reivindica-sopoerte-psicologico

    PRESS RELEASE
    21 Apr 2024
    Share Share
    Ferrer offers $122M biobucks for ex-US license to Verge ALS drug
    Ferrer offers $122M biobucks for ex-US license to Verge ALS drug

    25 Mar 2024

    // PRESS RELEASE

    https://www.ferrer.com/en/node/19931

    PRESS RELEASE
    25 Mar 2024
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Interquim Popup full-view
    Process Development & Scale-Up
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    FDA

    read-more
    read-more

    01

    FDA Audited

    USA
    arrow
    Biotech Digital Meet
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2019-09-27

    Interquim SA

    City : Sant Cugat Del Valles

    State :

    Country/Area : ES

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2019-09-27

    Interquim

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    FDA Audited

    USA
    arrow
    Biotech Digital Meet
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2018-12-20

    Interquim SA

    City : Sant Cugat Del Valles

    State :

    Country/Area : ES

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2018-12-20

    Interquim

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    03

    FDA Audited

    USA
    arrow
    Biotech Digital Meet
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2017-06-02

    Interquim SA

    City : Sant Cugat del Valles

    State :

    Country/Area : ES

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2017-06-02

    Interquim

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    04

    FDA Audited

    USA
    arrow
    Biotech Digital Meet
    Not Confirmed

    District Decision : Official Action Indicated

    Inspection End Date : 2016-05-06

    Interquim SA

    City : Sant Cugat del Valles

    State :

    Country/Area : ES

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : Official Action Indicated

    Inspection End Date : 2016-05-06

    Interquim

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    05

    FDA Audited

    USA
    arrow
    Biotech Digital Meet
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2013-10-11

    Interquim SA

    City : Sant Cugat Del Valles

    State :

    Country/Area : ES

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2013-10-11

    Interquim

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    06

    FDA Audited

    USA
    arrow
    Biotech Digital Meet
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2011-09-09

    Interquim SA

    City : Sant Cugat Del Valles

    State :

    Country/Area : ES

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2011-09-09

    Interquim

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Others

    read-more
    read-more

    ABOUT THIS PAGE

    Contact Interquim SA and get a quotation

    Interquim SA is a supplier offers 30 products (APIs, Excipients or Intermediates).

    Find a price of Rivastigmine bulk with DMF, CEP, JDMF offered by Interquim SA

    Find a price of Celecoxib bulk with DMF, CEP offered by Interquim SA

    Find a price of Olmesartan Medoxomil bulk with CEP, JDMF offered by Interquim SA

    Find a price of Ozenoxacin bulk with DMF, JDMF offered by Interquim SA

    Find a price of Rotigotine bulk with DMF, CEP offered by Interquim SA

    Find a price of Sertaconazole Nitrate bulk with DMF, CEP offered by Interquim SA

    Find a price of Solifenacin Succinate bulk with DMF, CEP offered by Interquim SA

    Find a price of Tadalafil bulk with CEP, JDMF offered by Interquim SA

    Find a price of Telmisartan bulk with CEP, JDMF offered by Interquim SA

    Find a price of Tolterodine Tartrate bulk with DMF, CEP offered by Interquim SA

    Find a price of Aripiprazole bulk with DMF offered by Interquim SA

    Find a price of Aripiprazole Lauroxil bulk with DMF offered by Interquim SA

    Find a price of Ciclopirox bulk with DMF offered by Interquim SA

    Find a price of Ciclopirox Olamine bulk with CEP offered by Interquim SA

    Find a price of Ferric Carboxymaltose bulk with DMF offered by Interquim SA

    Find a price of Imiquimod bulk with DMF offered by Interquim SA

    Find a price of Lifitegrast bulk with DMF offered by Interquim SA

    Find a price of Paliperidone Palmitate bulk with DMF offered by Interquim SA

    Find a price of Risperidone bulk with DMF offered by Interquim SA

    Find a price of Rivastigmine Tartrate bulk with CEP offered by Interquim SA

    Find a price of Roflumilast bulk with DMF offered by Interquim SA

    Find a price of Edaravone bulk offered by Interquim SA

    Find a price of Ferric Derisomaltose bulk offered by Interquim SA

    Find a price of Lumateperone Tosylate bulk offered by Interquim SA

    Find a price of Paliperidone bulk offered by Interquim SA

    Find a price of Pimavanserin Tartrate bulk offered by Interquim SA

    Find a price of Rasagiline Tartrate bulk offered by Interquim SA

    Find a price of Tapinarof bulk offered by Interquim SA

    Find a price of Torsemide bulk offered by Interquim SA

    Find a price of Uridine Triphosphate Trisodium bulk offered by Interquim SA

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search